B. Guy et al., Design, characterization and preclinical efficacy of a cationic lipid adjuvant for influenza split vaccine, VACCINE, 19(13-14), 2001, pp. 1794-1805
We prepared a series of cationic lipid vesicles comprising a cationic chole
sterol derivative, DC-Chol with or without a neutral phospholipid, DOPC or
DOPE. The vesicles were tested for their ability to bind and adjuvant split
inactivated influenza vaccines. We found that DC-Chol-containing liposomes
are capable to strongly bind influenza vaccine antigens upon simple mixing
with the vaccine. The resulting formulations induced robust anti-influenza
immune responses both after s.c. and i.n. administration in BALB/c mice wh
ile neutral Cholesterol/DOPC liposomes displayed virtually no stable antige
n binding and no adjuvant effect. The parenteral adjuvant effect of DC-Chol
on trivalent split influenza vaccines was then confirmed in outbred mice a
nd monkeys. Among the most potent formulations tested, a simple mixture of
the vaccine with a microfluidized dispersion of DC-Chol in an aqueous buffe
r is being considered for further development to produce an improved influe
nza vaccine. (C) 2001 Elsevier Science Ltd. All rights reserved.